Drug
Ruboxistaurin clinical trials
Also written LY333531 and Arxxant.
Includes 3 studies of Ruboxistaurin mesylate.
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2002 (5)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 5 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 2 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
Chromaderm, Inc. (10) · Eli Lilly and Company (2) · Brigham and Women's Hospital (1) · University of Tennessee (1)
Studies
Open first, then newest update. How each study uses ruboxistaurin is read from its arms, and is right about nine times in ten.
Testing it · 14
- Ruboxistaurin in New York Heart Failure Classification III-IV PatientsWithdrawnPhase 1/2University of TennesseeNCT02769611Written as Ruboxistaurin
- The Effect of LY333531 on Protein in the Urine in Patients With Type 2 DiabetesCompletedPhase 2Chromaderm, Inc.NCT00044148Written as LY333531
- Reduction in the Occurrence of Center-Involved Diabetic Macular EdemaCompletedPhase 3Chromaderm, Inc.NCT00090519Written as ruboxistaurin
- Treatment for Completers of the Study B7A-MC-MBCMCompletedPhase 3Chromaderm, Inc.NCT00266695Written as Ruboxistaurin
- Effect of Ruboxistaurin on Clinically Significant Macular EdemaCompletedPhase 3Chromaderm, Inc.NCT00133952Written as Ruboxistaurin
- Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 StudyCompletedPhase 3Chromaderm, Inc.NCT00604383Written as ruboxistaurin
- Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes MellitusCompletedPhase 3Chromaderm, Inc.NCT00297401Written as ruboxistaurin
- Effect of LY333531 on Vascular and Neural FunctionsCompletedPhase 2Chromaderm, Inc.NCT00482976Written as Ruboxistaurin
- Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes MellitusCompletedPhase 1Chromaderm, Inc.NCT00552227Written as ruboxistaurin
- Treatment for Symptomatic Peripheral Neuropathy in Patients With DiabetesCompletedPhase 3Chromaderm, Inc.NCT00044408Written as Ruboxistaurin mesylate
- The Effect of Ruboxistaurin on Small Fiber FunctionCompletedPhase 2Chromaderm, Inc.NCT00190970Written as Ruboxistaurin
- Signaling Mechanisms and Vascular Function in Diabetes MellitusCompletedPhase 2/3Brigham and Women's HospitalNCT00761852Written as Ruboxistaurin
- Treatment for Symptomatic Peripheral Neuropathy in Patients With DiabetesCompletedPhase 3Eli Lilly and CompanyNCT00044395Written as Ruboxistaurin mesylate
- Treatment of Peripheral Neuropathy in Patients With DiabetesCompletedPhase 3Eli Lilly and CompanyNCT00044421Written as Ruboxistaurin mesylate
Codes
What other systems call ruboxistaurin · ClinicalTrials.gg INT003900
- MeSH (NLM) C099154ruboxistaurinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 721809WQCPRUBOXISTAURINConfirmed FDA, NLM, Wikidata
- RxNorm 394407One source Wikidata
- Wikidata Q7376181ruboxistaurinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66524RuboxistaurinOne source FDA
- DrugBank DB11829One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C099154 | ruboxistaurin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 721809WQCP | RUBOXISTAURIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 394407 | — | One source Wikidata |
| Wikidata | Q7376181 | ruboxistaurin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66524 | Ruboxistaurin | One source FDA |
| DrugBank | DB11829 | — | One source Wikidata |
Also registered as ruboxistaurin mesylate monohydrate (UNII 4TY24FTS56).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.